Lake Street Capital Issues Positive Forecast for Hyperfine (NASDAQ:HYPR) Stock Price

Hyperfine (NASDAQ:HYPR) had its target price lifted by Lake Street Capital from $2.00 to $2.50 in a research note released on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Hyperfine in a report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $1.45.

Hyperfine Price Performance

NASDAQ:HYPR opened at $1.21 on Thursday. The business’s 50-day moving average is $1.15 and its two-hundred day moving average is $1.20. Hyperfine has a 12 month low of $0.53 and a 12 month high of $2.22. The firm has a market capitalization of $117.58 million, a PE ratio of -2.75 and a beta of 1.09.

Hyperfine (NASDAQ:HYPR) last issued its quarterly earnings data on Wednesday, March 18th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. Hyperfine had a negative return on equity of 99.14% and a negative net margin of 262.29%.The company had revenue of $5.29 million for the quarter, compared to analysts’ expectations of $5.30 million. Equities analysts anticipate that Hyperfine will post -0.57 EPS for the current year.

Hedge Funds Weigh In On Hyperfine

Institutional investors have recently added to or reduced their stakes in the company. State Street Corp grew its stake in shares of Hyperfine by 6.1% during the fourth quarter. State Street Corp now owns 265,195 shares of the company’s stock valued at $260,000 after acquiring an additional 15,200 shares in the last quarter. Sanctuary Advisors LLC lifted its stake in shares of Hyperfine by 130.9% in the fourth quarter. Sanctuary Advisors LLC now owns 39,938 shares of the company’s stock worth $39,000 after acquiring an additional 22,638 shares in the last quarter. XTX Topco Ltd lifted its stake in shares of Hyperfine by 47.9% in the fourth quarter. XTX Topco Ltd now owns 80,735 shares of the company’s stock worth $79,000 after acquiring an additional 26,165 shares in the last quarter. Tortoise Investment Management LLC boosted its holdings in Hyperfine by 60.0% in the fourth quarter. Tortoise Investment Management LLC now owns 72,000 shares of the company’s stock valued at $71,000 after purchasing an additional 27,000 shares during the last quarter. Finally, EP Wealth Advisors LLC purchased a new position in Hyperfine in the fourth quarter valued at about $34,000. Institutional investors and hedge funds own 15.03% of the company’s stock.

Key Headlines Impacting Hyperfine

Here are the key news stories impacting Hyperfine this week:

• Positive Sentiment: Lake Street Capital raised its price target to $2.50 and upgraded HYPR to a “buy” — the new target implies roughly 106.6% upside from the current quoted level around $1.21. This analyst support can attract demand as shares trade below recent targets. Lake Street Upgrade / Benzinga
• Positive Sentiment: Management outlined an aggressive 55% revenue growth target for 2026 and said it is expanding adoption of the Swoop portable MRI into more hospitals and neurology offices — a sign of accelerating commercial traction if execution holds. Hyperfine revenue-growth target / Seeking Alpha
• Positive Sentiment: Company highlights product progress: launch of the second‑generation Swoop scanner and Optive AI software plus expansion into the neurology office setting — these product and market moves improve the growth story if they translate to sales. Business Wire: Q4 & product update
• Neutral Sentiment: Full Q4 2025 earnings call transcript and highlights are available for detail on guidance, sales cadence, and margin outlook — useful for modeling but not a market mover by itself. Q4 2025 Earnings Call Transcript / Yahoo
• Negative Sentiment: Q4 results: EPS loss of ($0.06) slightly beat estimates but revenue of $5.29M essentially matched consensus (~$5.30M). The company remains unprofitable with very negative net margin and return on equity, keeping capital needs and cash burn as key near-term risks — a likely driver of downward pressure on the stock. MarketBeat: Q4 results & metrics

About Hyperfine

Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.

The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.